Tirz (GLP-1)
Dual Incretin Peptide for Metabolic, Endocrine, and Obesity Research

Tirz is a synthetic dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This novel peptide is of great interest in metabolic and endocrine research, particularly in models involving glucose regulation, energy balance, and weight management pathways.

Product Overview
Supplied in lyophilized format, Tirz is available for in vitro and preclinical exploration in models evaluating insulin sensitivity, adipocyte function, and incretin hormone signaling.

Key Research Attributes:

• GLP-1 and GIP Dual Activity: Mimics endogenous incretins to enhance glucose-stimulated insulin secretion and satiety signaling.
• Insulin Sensitivity: Explored in studies assessing improved glucose uptake and pancreatic beta-cell preservation.
• Body Weight Modulation: Utilized in obesity-related research targeting reduced energy intake and enhanced metabolic expenditure.
• Chronic Disease Models: Investigated in laboratory models of metabolic syndrome, type 2 diabetes, and lipid metabolism disorders.

Applications in Scientific Research

• Incretin pathway and peptide hormone signaling studies
• Glucose homeostasis and insulin secretion models
• Obesity and energy regulation research
• Liver lipid metabolism and hepatic steatosis studies
• Endocrinology-focused preclinical experiments

Format and Storage
Form: Lyophilized powder
Purity: >99%
Storage: Store at -20°C in a dry, dark location
Reconstitution: Reconstitute with sterile bacteriostatic water under aseptic conditions

Disclaimer: Tirz (GLP-1) is provided exclusively for laboratory-based, in vitro scientific research. It is not intended for human or veterinary use. All handling must comply with institutional and legal safety requirements.